Rimonabant (acomplia®), obésité et diabiète de type 2
Le rimonabant (Acomplia®) est une molécule au mécanisme d'action original, antagoniste du récepteur CB1 du système endocannabinoïde qui joue un rôle majeur dans la régulation de l'équilibre énergétique du corps.
BESSIERES, Hélène +1 more
core
Discrete Choice Experiment (DCE) as a Tool to Elicit Patient Preferences in a Complex Benefit-Risk Evaluation: A Case Study. [PDF]
E JY +5 more
europepmc +1 more source
Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies. [PDF]
Costa GPA +7 more
europepmc +1 more source
Rimonabant n,n-dimethylformamide solvate, and method for preparing same
The invention relates to a rimonabant N,N-dimethylformamide solvate, and to a method for preparing the ...
Coquerel, Gérard, Fours, Baptiste
core
Cannabinoid 1 receptor occupancy and neurovascular responses induced by agonist, antagonist/inverse-agonist and potential modulator in non-human primate brains: PET/fMRI study. [PDF]
Yoo CH +5 more
europepmc +1 more source
Glucocorticoid-endocannabinoid crosstalk in the ventrolateral periaqueductal gray (vlPAG) promotes pain resolution. [PDF]
Coutens B +9 more
europepmc +1 more source
Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. [PDF]
Rabl K +5 more
europepmc +1 more source
Melatonin mitigates hormonal toxicity in cannabis-treated female Wistar rats: involvement of cannabinoid receptor. [PDF]
Oluwasola A.
europepmc +1 more source
Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes. [PDF]
Vázquez-Oliver A +8 more
europepmc +1 more source
Short Communication: The Peripheral Cannabinoid CB<sub>1</sub> Receptor Antagonist AM6545 Modifies Cardiovascular Effects of Endocannabinoids in DOCA-Salt Rats. [PDF]
Remiszewski P +5 more
europepmc +1 more source

